Literature DB >> 17545627

Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinoma.

Shayna E A Street1, Nadeen Zerafa, Manuela Iezzi, Jennifer A Westwood, John Stagg, Piero Musiani, Mark J Smyth.   

Abstract

The concept of tumor immune surveillance has been supported by several recent studies in mice which show that immune effector mechanisms suppress hematologic malignancy. However, because the most common forms of human cancer are epithelial in origin, and comparatively very little data supports the immune surveillance of epithelial malignancies, we have chosen to evaluate the role of perforin-mediated cytotoxicity in the prevention of BALB/c Her2/neu-induced mammary cancer. Interestingly, perforin significantly delayed the onset of mammary tumorigenesis and reduced the number of mammary tumors without improving survival. Natural killer cell, but not CD8+ T cell, depletion resulted in a similar phenotype to perforin deficiency in this regard. Histologic analysis further indicated that the effect of perforin was most evident during the earliest stages of carcinogenesis rather than prior to or during the hyperplastic phase. This data suggests that perforin may mediate some suppression of epithelial carcinogenesis by intervening early in the tumor development process.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17545627     DOI: 10.1158/0008-5472.CAN-06-4084

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  The breast tumor microenvironment alters the phenotype and function of natural killer cells.

Authors:  Tamara Krneta; Amy Gillgrass; Marianne Chew; Ali A Ashkar
Journal:  Cell Mol Immunol       Date:  2015-08-17       Impact factor: 11.530

Review 2.  Tissue-Resident Cytolytic Innate Lymphocytes in Cancer.

Authors:  Briana G Nixon; Ming O Li
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

Review 3.  T Cells and Regulated Cell Death: Kill or Be Killed.

Authors:  Johan Spetz; Adam G Presser; Kristopher A Sarosiek
Journal:  Int Rev Cell Mol Biol       Date:  2018-08-29       Impact factor: 6.813

4.  Immunosurveillance and immunoediting in MMTV-PyMT-induced mammary oncogenesis.

Authors:  Emilie T E Gross; Semi Han; Prasantha Vemu; Carlos D Peinado; Martin Marsala; Lesley G Ellies; Jack D Bui
Journal:  Oncoimmunology       Date:  2016-12-14       Impact factor: 8.110

5.  Activation of regulatory T cells instigates functional down-regulation of cytotoxic T lymphocytes in human breast cancer.

Authors:  Chao-Hsu Li; Wen-Hong Kuo; Wen-Chun Chang; Su-Cheng Huang; King-Jen Chang; Bor-Ching Sheu
Journal:  Immunol Res       Date:  2011-10       Impact factor: 2.829

6.  The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis.

Authors:  Silvio Bandini; Marco Macagno; Albana Hysi; Stefania Lanzardo; Laura Conti; Amanda Bello; Federica Riccardo; Roberto Ruiu; Irene Fiore Merighi; Guido Forni; Manuela Iezzi; Elena Quaglino; Federica Cavallo
Journal:  Oncoimmunology       Date:  2016-11-08       Impact factor: 8.110

Review 7.  Tissue-resident cytotoxic innate lymphoid cells in tumor immunosurveillance.

Authors:  Efstathios G Stamatiades; Ming O Li
Journal:  Semin Immunol       Date:  2019-03-21       Impact factor: 11.130

8.  Cancer Immunosurveillance by Tissue-Resident Innate Lymphoid Cells and Innate-like T Cells.

Authors:  Saïda Dadi; Sagar Chhangawala; Benjamin M Whitlock; Ruth A Franklin; Chong T Luo; Soyoung A Oh; Ahmed Toure; Yuri Pritykin; Morgan Huse; Christina S Leslie; Ming O Li
Journal:  Cell       Date:  2016-01-21       Impact factor: 41.582

9.  Perforin-mediated suppression of B-cell lymphoma.

Authors:  Paul Bolitho; Shayna E A Street; Jennifer A Westwood; Winfried Edelmann; Duncan Macgregor; Paul Waring; William K Murray; Dale I Godfrey; Joseph A Trapani; Ricky W Johnstone; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-05       Impact factor: 11.205

Review 10.  Targeting natural killer cells in solid tumors.

Authors:  Guillaume Habif; Adeline Crinier; Pascale André; Eric Vivier; Emilie Narni-Mancinelli
Journal:  Cell Mol Immunol       Date:  2019-03-25       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.